Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2026-05-11 Capital/Financing Update
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 92% confidence The document is a press release announcing the successful oversubscription of a €6 million capital increase, detailing the issuance of new shares, share subscription warrants (BSA), use of proceeds, settlement, and impact on share capital structure. This is a direct announcement of a fundraising/capital structure change transaction rather than a full financial report or AGM materials. Therefore, it falls under the Capital/Financing Update category.
2026-05-11 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release by Theraclion announcing the successful oversubscribed capital increase (augmentation de capital), detailing the amount raised, issuance of new shares and warrants (BSA), use of proceeds, changes in share capital and ownership structure. It is clearly an update on a fundraising and capital structure change. Therefore, it fits the Capital/Financing Update category (CAP).
2026-05-11 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 85% confidence The document is a webinar invitation for a presentation of Theraclion’s planned capital increase of €6M (augmentation de capital). It is centered on fundraising/financing activity rather than a formal report, dividend notice, or regulatory filing. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-04-22 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 88% confidence The document is a press release detailing the terms of a new capital increase through the issuance of shares with attached warrants (ABSA), including subscription price, ratios, periods, commitment levels, legal framework, and use of proceeds. This is clearly an update on a fundraising and capital structure change, fitting the “Capital/Financing Update” category. It is not an annual or interim report, not a proxy or dividend notice, nor a management change or earnings release. Therefore it is classified as CAP.
2026-04-20 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Share Issue/Capital Change Classification · 92% confidence The document is a press release detailing the launch of a capital increase (‘augmentation de capital’) by issuance of new actions with attached share warrants (ABSA), including subscription price, parities, rights trading periods, underwriting commitments, and legal and procedural modalities. This falls squarely under an announcement of a new share issue and changes to the company’s capital structure.
2026-04-20 French
Inside Information / News release on accounts, results
Earnings Release Classification · 90% confidence The document is a press release titled “Theraclion publishes its 2025 financial results and provides an update on its outlook.” It contains headline financial metrics for full year 2025 (revenue, expenses, net result), discussion of strategic achievements, outlook commentary, and high-level operating and cash flow tables. It is a standalone announcement of annual results rather than the full statutory annual report or regulatory filing. This matches the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-04-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.